Shares are up more than 50% already this year, as the story surrounding the company’s GLP-1 drugs gets better and better.
Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs as the company gears up to announce its third-quarter earnings. Wall ...
Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...
产能狙击:在美国市场,礼来已成功克服了早期的供应链难题,使得Zepbound(替尔泊肽)的所有剂量在美国市场上都可以得到供应。相比之下,诺和诺德在向美国市场供应Wegovy(司美格鲁肽)方面仍然面临困难。
按照协议,礼来公司将启动一项“真实世界”研究,旨在了解替西帕肽(tirzepatide,其Zepbound和Mounjaro药物背后的GLP-1受体激动剂药物)如何影响减肥、糖尿病预防和肥胖相关并发症的预防,以更好地为英国国家卫生服务局(NHS)应对 ...
智通财经APP获悉,美国食品药品管理局(FDA)宣布,礼来公司(LLY.US)的畅销减肥和糖尿病药物Zepbound和Mounjaro的短缺问题已得到解决,这可能会对市场上流行的仿制品造成冲击。此前,由于药物短缺,FDA允许药房出售未经严格测试的仿制 ...
由此产生的市场狂热情绪推动诺和诺德股价在此后几年里迅速飙升,使得这家丹麦医药公司成为欧洲市值最大的上市公司。礼来减肥药的批准时间则大幅落后,去年11月才获得批准销售抗击肥胖的药物Zepbound。
Scholar Rock (SRRK.US)在上个月完成了其肌生成抑制素靶向药物apitegromab的2期临床试验。这项名为EMBRAZE的研究旨在展示其在使用GLP-1类药物治疗肥胖的个体中保留瘦肌肉量的概念验证。
智通财经APP获悉,礼来公司(LLY.US)正在探索其减肥药Zepbound的新用途,以降低糖尿病患者和其他高风险人群的发病率,即使他们并未超重。该公司首席 ...
【礼来CEO称减肥药Zepbound有望明年在日本获批】礼来公司首席执行官周五表示,减肥药Zepbound有望明年在日本获批。
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food and Drug Administration (FDA). The FDA updated its drug shortage ...
If you buy through links on this page, we may earn a small commission. Here’s our process. Zepbound (tirzepatide) is an injectable drug for weight loss in those with obesity or those with ...